🇺🇸 FDA
Pipeline program

ETEPLIRSEN (AVI-4658)

4658-402

Phase 3 small_molecule active

Quick answer

ETEPLIRSEN (AVI-4658) for Duchenne Muscular Dystrophy is a Phase 3 program (small_molecule) at Sarepta Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Sarepta Therapeutics
Indication
Duchenne Muscular Dystrophy
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials